{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Femtech Health Podcast","title":"From Taboo to Treatment: How 400 Proteins in Menstrual Blood May Be the Future of Preventative Care","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/93644afb\"></iframe>","width":"100%","height":180,"duration":3442,"description":"In this episode, Dr. Sara Naseri, CEO and co-founder of Qvin, shares the powerful origin story behind the Q-Pad — a revolutionary menstrual health technology transforming the way women monitor their health.\n\nQvin is pioneering the use of menstrual blood to provide clinically relevant, accessible diagnostics for conditions like diabetes, thyroid imbalance, fertility challenges, and even cervical cancer. Dr. Naseri discusses her 10-year journey from med school to FDA clearance, the data gap in women's health, and how menstrual blood — long stigmatized and overlooked — holds incredible untapped potential for global healthcare impact.\nFrom redefining preventative care to making diagnostics available at home, this conversation is a deep dive into innovation, accessibility, and the future of femtech.\nTimestamps & Sections:(00:00) - Introduction & Background\nDr. Sara Nasseri, CEO and Co-Founder of Qvin, introduces the company and its mission to empower women's health through the Q-Pad—a revolutionary diagnostic menstrual pad.\n(01:00) - Origin of the Idea\nSara shares how the concept of using menstrual blood for diagnostics was born during medical school and the long journey that followed.\n(04:00) - Diagnostic Utility of Menstrual Blood\nDiscussion of early research, the lack of existing data on menstrual blood, and Qvin’s role in pioneering this new area of science.\n(07:00) - The Q-Pad's Functionality & Empowerment\nHow the Q-Pad works, and why accessibility, affordability, and user empowerment are core to its design.\n(09:00) - Clinical Applications & FDA Clearance\nDetails on the Q-Pad’s FDA clearance for hemoglobin A1c monitoring and its ability to support chronic condition management like diabetes.\n(13:00) - Expanding Use Cases: Cervical Cancer & Beyond\nExploration of new biomarkers and the potential for non-invasive cervical cancer screening through the Q-Pad.\n(17:00) - Tracking Fertility, Thyroid, and Inflammation\nFuture plans to roll out clinical-grade insights into...","thumbnail_url":"https://img.transistorcdn.com/G2MWXzbgUUOyGMJWFx-3EA_ygWSaodljCLpu3Y8ptwo/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQ2MTY4LzE2OTc2/NTQ2NTYtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}